St Louis Financial Loads Up on AbbVie ( ABBV ) With 14,600 Shares Buy
St. Louis Financial Planners Asset Management, LLC initiated a new stake in AbbVie ( NYSE:ABBV ) , acquiring 14,630 shares for an estimated $3.39 million in Q3 2025.According to a Securities and Exchange Commission ( SEC ) filing dated October 02, 2025, St. Louis Financial Planners Asset ...
MRK Stock Up Nearly 14% So Far This Week: What's Driving It?
Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.
Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?
Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.
What Does the Market Think About AbbVie Inc? - AbbVie ( NYSE:ABBV )
AbbVie Inc's ( NYSE:ABBV ) short interest as a percent of float has risen 8.05% since its last report. According to exchange reported data, there are now 16.56 million shares sold short, which is 0.94% of all regular shares that are available for trading.
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer ( SITC ) 40th Annual Meeting
WALTHAM, Mass., Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- Xilio Therapeutics, Inc. ( Nasdaq: XLO ) , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced multiple upcoming poster presentations at the ...
AbbVie ( ABBV ) Stock Sinks As Market Gains: Here's Why
In the closing of the recent trading day, AbbVie (ABBV) stood at $236.56, denoting a -3.2% move from the preceding trading day.
Stock Market News for Oct 2, 2025
Wall Street closed higher on Wednesday, driven by healthcare stocks.
Why AbbVie Stock Cruised to an Almost 6% Gain Today
A new expansion project and a win for a peer pharmaceutical company were attracting investors to the shares.
Company News for Oct 1, 2025
Companies in The News Are: ...
Trump's pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
Pfizer's deal with Trump was a relief to the pharma industry, signaling that drugmakers could strike similar deals that would make them immune to tariffs.
Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs?
AI's growing role in cancer research, and a new federal push for pediatric oncology, are powering gains in key healthcare ETFs.
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
WELLESLEY HILLS, Mass., Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Climb Bio, Inc. ( Nasdaq: CLYM ) , a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D., ...
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
If you are looking for dividend stocks that can provide a reliable, long-term income stream, consider buying AbbVie, Coca-Cola, and Chevron.
A Closer Look at AbbVie's Options Market Dynamics - AbbVie ( NYSE:ABBV )
Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie ( NYSE:ABBV ) we detected 47 trades. If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish ...
Umoja Biopharma Announces that UB-VV111 Receives FDA Fast Track Designation for Relapsed/Refractory B-Cell Malignancies
SEATTLE, Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, announced today that the U.S.
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever
Dividend stocks can be a more predictable stream of income for investors.
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Tokyo, Japan and Cambridge and London, UK, 30 September 2025 - Nxera Pharma Co., Ltd. ( "Nxera" or "the Company". TSE 4565 ) announces that it has reached a second important R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a ...
Here's How Much $100 Invested In AbbVie 5 Years Ago Would Be Worth Today - AbbVie ( NYSE:ABBV )
AbbVie ( NYSE: ABBV ) has outperformed the market over the past 5 years by 6.25% on an annualized basis producing an average annual return of 20.98%. Currently, AbbVie has a market capitalization of $394.19 billion.
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
AbbVie Inc. ( ABBV ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
NEW YORK, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director.
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( NASDAQ: RPRX ) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director.
Should SPDR Portfolio S&P 500 High Dividend ETF ( SPYD ) Be on Your Investing Radar?
Style Box ETF report for ...
1 Top ETF I Wouldn't Hesitate to Invest $1,000 Into Right Now
This fund makes it easy to invest in the top dividend stocks.
5 Dividend Powerhouses to Buy and Never Sell
These blue-chip giants have paid shareholders through wars, recessions, and pandemics.
These 3 ETFs Could Shine as Interest Rates Fall
These ETFs hold dividend-paying stocks that should do well with interest rates dropping.
Decoding AbbVie's Options Activity: What's the Big Picture? - AbbVie ( NYSE:ABBV )
Investors with a lot of money to spend have taken a bearish stance on AbbVie ( NYSE: ABBV ) . We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025
OSE Immunotherapeutics Reports its Cash Position as of June ...
Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?
VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.
Is iShares Core High Dividend ETF ( HDV ) a Strong ETF Right Now?
Smart Beta ETF report for ...
3 Top Dividend Stocks to Buy and Hold Forever
These blue chip dividend stocks offer both income and growth potential.
Where Will AbbVie Be in 5 Years?
This big pharmaceutical company should be significantly bigger five years from now.
AbbVie ( ABBV ) Declines More Than Market: Some Information for Investors
AbbVie (ABBV) concluded the recent trading session at $219.99, signifying a -1.18% move from its prior day's close.
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies - Novartis ( NYSE:NVS )
A U.S. federal judge has rejected challenges by two pharmaceutical manufacturers seeking to block a Maine law that regulates the use of contract pharmacies under the federal 340B drug discount program. Novartis AG NVS and AbbVie Inc.
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.
Can PFE Successfully Return to the Obesity Space With Metsera Buyout?
Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.
Halozyme Therapeutics and Synopsys have been highlighted as Zacks Bull and Bear of the Day
Halozyme shines with strong growth and partnerships, while Synopsys struggles after earnings miss and lowered outlook.
Bull of the Day: Halozyme Therapeutics ( HALO )
The Street bailed on HALO in the spring, right before a summer rally to new highs on strong growth ...
1 Top Dividend Stock to Buy and Hold Forever
The stock has outperformed the broader market since its 2013 IPO, and can still do so over the long run.
What Is One of the Best Pharmaceutical Stocks to Buy Right Now?
There aren't many companies in the industry that offer an excellent combination of growth and income.
Forever Dividend Stocks: 3 Income Stocks I Never Plan to Sell
Never say never? Maybe not with these great dividend stocks.
ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK
• Mohit Rawat appointed CEO, bringing deep biopharma leadership and a track record of driving innovations in drug discovery to commercial and transactional success.
ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK
Mohit Rawat appointed CEO, bringing deep biopharma leadership and a track record of driving innovations in drug discovery to commercial and transactional success; former CEO Robin Carr transitions to new CTO role Expanded senior team across clinical, CMC, regulatory and business development in ...
Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum
NEW YORK, Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in a fireside chat at Bernstein's 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET.
Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will participate in a fireside chat at Bernstein's 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET.
Boost Your Portfolio With These Top-Ranked ETFs
With the Fed's first 2025 rate cut and upgraded growth outlook, ETFs in tech, financials, industrials and health care could benefit from momentum.
The Zacks Analyst Blog Highlights AbbVie, ServiceNow, Boeing, Tucows and and Ampco-Pittsburgh
Zacks spotlights AbbVie, ServiceNow, Boeing, Tucows, and Ampco-Pittsburgh, detailing growth drivers, headwinds, and industry positioning.
CHMP recommends EU approval of Roche's subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma
Basel, 19 September - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use ( CHMP ) has recommended the approval of a subcutaneous ( SC ) formulation of Lunsumio® ( mosunetuzumab ) for the treatment of adult ...
